Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation

Affiliations

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
² University of Iowa Hospitals, Iowa City, Iowa.
³ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom. Electronic address: gregory.lip@liverpool.ac.uk.

Editorial

Ameenathul M Fawzy et al. Am Heart J. 2019 Feb.

. 2019 Feb:208:120-122.

doi: 10.1016/j.ahj.2018.10.003. Epub 2018 Oct 31.

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
² University of Iowa Hospitals, Iowa City, Iowa.
³ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom. Electronic address: gregory.lip@liverpool.ac.uk.

No abstract available

Comment on

Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial.
Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB; ARISTOTLE Investigators. Alexander KP, et al. Am Heart J. 2019 Feb;208:123-131. doi: 10.1016/j.ahj.2018.09.017. Epub 2018 Nov 22. Am Heart J. 2019. PMID: 30579505 Clinical Trial.